Early vs. Late Gestational Diabetes: Comparison between Two Groups Diagnosed by Abnormal Initial Fasting Plasma Glucose or Mid-Pregnancy Oral Glucose Tolerance Test

Carregando...
Imagem de Miniatura
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Citação
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, v.19, n.21, article ID 13719, 9p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Gestational diabetes mellitus (GDM) is one of the most common complications in pregnancy. It may be diagnosed using a fasting plasma glucose (FPG) early in pregnancy (eGDM) or a 75-g oral glucose tolerance test (OGTT) (late GDM). This retrospective cohort of women with GDM presents data from 1891 patients (1004 in the eGDM and 887 in the late GDM group). Student's t-test, chi-squared or Fisher's exact test and the Bonferroni test for post hoc analysis were used to compare the groups. Women with eGDM had higher pre-pregnancy BMI, more frequent family history of DM, more frequent history of previous GDM, and were more likely to have chronic hypertension. They were more likely to deliver by cesarean section and to present an abnormal puerperal OGTT. Even though they received earlier treatment and required insulin more frequently, there was no difference in neonatal outcomes. Diagnosing and treating GDM is necessary to reduce complications and adverse outcomes, but it is still a challenge. We believe that women with eGDM should be treated and closely monitored, even though this may increase healthcare-related costs.
Palavras-chave
gestational diabetes, early-onset GDM, oral glucose tolerance test, IADPSG
Referências
  1. Agarwal MM, 2014, DIABETES RES CLIN PR, V103, P341, DOI 10.1016/j.diabres.2013.10.012
  2. Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS15, DOI 10.2337/dc21-S002
  3. American Diabetes Association Professional Practice Committee, 2022, Diabetes Care, V45, pS17, DOI 10.2337/dc22-S002
  4. [Anonymous], 2018, Obstet Gynecol, V131, pe49, DOI 10.1097/AOG.0000000000002501
  5. Battarbee AN, 2018, AM J PERINAT, V35, P354, DOI 10.1055/s-0037-1607284
  6. Benhalima K, 2021, J CLIN ENDOCR METAB, V106, pE836, DOI 10.1210/clinem/dgaa831
  7. Bhattacharya Saptarshi, 2021, Med Sci (Basel), V9, DOI 10.3390/medsci9040059
  8. Bozkurt L, 2015, J CLIN ENDOCR METAB, V100, P1113, DOI 10.1210/jc.2014-4055
  9. Corrado F, 2012, DIABETES METAB, V38, P458, DOI 10.1016/j.diabet.2012.03.006
  10. Cosson E, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/8921712
  11. Cosson E, 2015, DIABETIC MED, V32, P189, DOI 10.1111/dme.12631
  12. Cosson E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10173904
  13. Hod M, 2015, INT J GYNECOL OBSTET, V131, pS173, DOI [10.1016/S0020-7292(15)30007-2, 10.1016/S0020-7292(15)30033-3]
  14. Lynch CM, 2008, AM J PERINAT, V25, P163, DOI 10.1055/s-2008-1061496
  15. McIntyre HD, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0098-8
  16. Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943
  17. Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848
  18. Nankervis A., 2014, MODIF JUNE, P1
  19. NICE, 2021, GUID DIAB PREGN MAN
  20. Paul JC, 2020, APPL NURS RES, V56, DOI 10.1016/j.apnr.2020.151341
  21. Pettersen-Dahl A, 2018, ACTA OBSTET GYN SCAN, V97, P212, DOI 10.1111/aogs.13265
  22. Roeder HA, 2019, AM J OBST GYNEC MFM, V1, P33, DOI 10.1016/j.ajogmf.2019.03.003
  23. Sweeting AN, 2016, DIABETES CARE, V39, P75, DOI 10.2337/dc15-0433
  24. Wang C, 2021, DIABETES RES CLIN PR, V174, DOI 10.1016/j.diabres.2021.108736
  25. Weiss JL, 2004, AM J OBSTET GYNECOL, V190, P1091, DOI 10.1016/j.ajog.2003.09.058
  26. World Health Organization, 2019, CLASS DIAB MELL
  27. Ye YZ, 2022, J CLIN ENDOCR METAB, V107, pE1541, DOI 10.1210/clinem/dgab841
  28. Zhu WW, 2013, DIABETES CARE, V36, P586, DOI 10.2337/dc12-1157